Banque Cantonale Vaudoise Purchases 1,633 Shares of NeoGenomics, Inc. (NASDAQ:NEO)

Banque Cantonale Vaudoise grew its position in shares of NeoGenomics, Inc. (NASDAQ:NEO) by 10.2% in the second quarter, according to its most recent filing with the SEC. The fund owned 17,575 shares of the medical research company’s stock after acquiring an additional 1,633 shares during the quarter. Banque Cantonale Vaudoise’s holdings in NeoGenomics were worth $244,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Natixis Advisors L.P. grew its stake in NeoGenomics by 103.4% in the 4th quarter. Natixis Advisors L.P. now owns 39,360 shares of the medical research company’s stock worth $636,000 after acquiring an additional 20,010 shares in the last quarter. Lisanti Capital Growth LLC purchased a new position in NeoGenomics during the 4th quarter valued at about $3,445,000. Charles Schwab Investment Management Inc. lifted its position in shares of NeoGenomics by 4.2% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,046,565 shares of the medical research company’s stock worth $16,933,000 after purchasing an additional 41,794 shares during the period. Dimensional Fund Advisors LP raised its stake in NeoGenomics by 0.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 3,006,523 shares of the medical research company’s stock worth $48,650,000 after buying an additional 18,603 shares in the last quarter. Finally, Mitsubishi UFJ Asset Management UK Ltd. lifted its holdings in NeoGenomics by 17.1% during the fourth quarter. Mitsubishi UFJ Asset Management UK Ltd. now owns 48,000 shares of the medical research company’s stock worth $777,000 after buying an additional 7,000 shares during the period. 98.50% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on NEO. Needham & Company LLC restated a “buy” rating and set a $19.00 price objective on shares of NeoGenomics in a research note on Tuesday, July 30th. Benchmark reaffirmed a “buy” rating and issued a $18.00 price target on shares of NeoGenomics in a report on Tuesday, July 30th. Finally, Stephens reiterated an “overweight” rating and set a $19.00 price objective on shares of NeoGenomics in a report on Tuesday, July 30th. Two research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat, NeoGenomics has an average rating of “Moderate Buy” and a consensus price target of $19.89.

NeoGenomics Price Performance

Shares of NASDAQ:NEO opened at $16.52 on Tuesday. NeoGenomics, Inc. has a twelve month low of $11.03 and a twelve month high of $21.22. The company has a current ratio of 2.01, a quick ratio of 1.93 and a debt-to-equity ratio of 0.37. The company has a market cap of $2.11 billion, a PE ratio of -25.03 and a beta of 1.18. The company’s 50 day moving average is $15.33 and its 200 day moving average is $14.89.

NeoGenomics (NASDAQ:NEO) last released its quarterly earnings data on Monday, July 29th. The medical research company reported $0.03 EPS for the quarter. NeoGenomics had a negative net margin of 12.50% and a negative return on equity of 2.72%. The business had revenue of $164.50 million for the quarter, compared to the consensus estimate of $161.82 million. During the same period in the prior year, the firm earned ($0.09) EPS. The business’s revenue for the quarter was up 12.0% on a year-over-year basis. On average, sell-side analysts forecast that NeoGenomics, Inc. will post -0.22 EPS for the current year.

NeoGenomics Company Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.